MaxCyte, Inc. Director/PDMR Shareholding (6925A)

TIDMMXCT TIDMTTM

RNS Number : 6925A

MaxCyte, Inc.

01 October 2020

MaxCyte, Inc.

("MaxCyte" or the "Company")

Director Dealings

Maryland, USA - 1 October 2020 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company, announces that J. Stark Thompson, Non-Executive Chairman of the Company, has exercised options over 25,000 shares of common stock of 0.1 pence of the Company ("Common Stock") ("Exercise"). In order to fund a near term personal tax liability, the 25,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock") have today been sold by Dr Thompson at a price of GBP3.55 pence per Common Stock ("Sale"). Dr Thompson has no current intention of making further sales of MaxCyte shares.

Following the Exercise and Sale, Dr Thompson's holding of Common Stock remains unchanged at a total of 110,918 Common Stock representing a total of 0.14% of the issued share capital of the Company. Dr Thompson holds a

further 241,333   options over Common Stock. 

Total voting rights

The New Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the above will be 77,305,169 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,405,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                        J. Stark Thompson 
      ==========================================  ============================================ 
 2     Reason for the notification 
      ======================================================================================== 
 a)    Position/status                             Non-Executive Chairman and PDMR 
      ==========================================  ============================================ 
 b)    Initial notification/Amendment              Initial notification 
      ==========================================  ============================================ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ======================================================================================== 
 a)    Name                                        MaxCyte, Inc. 
      ==========================================  ============================================ 
 b)    LEI                                         54930053YHXULRFCU991 
      ==========================================  ============================================ 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ======================================================================================== 
 a)    Description                                 Ordinary shares of 0.1 pence each 
        of the financial 
        instrument, 
        type of instrument 
      ==========================================  ============================================ 
 b)    Identification                              US57777K1060 
        Code 
      ==========================================  ============================================ 
 c)    Nature of the                               Exercise of options and Sale of Common 
        transaction                                 Stock by PDMR 
      ==========================================  ============================================ 
 d)    Price(s) and                                Price(s)                   Volume(s) 
        volume(s) 
      ==========================================  ==========================  ================ 
        GBP3.55                                                               25,000 
  ==========================================================================  ================ 
 e)    Aggregated information                      N/A (Single Transaction) 
        - Aggregated 
        volume 
        - Price 
      ==========================================  ============================================ 
 f)    Date of the                                 1.10.20 
        transaction 
      ==========================================  ============================================ 
 g)    Place of the                                London Stock Exchange, AIM Market (XLON) 
        transaction 
      ==========================================  ============================================ 
 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL) and is

headquartered in Gaithersburg, Maryland, US. For more information, visit        www.maxcyte.com   . 
 
 
   For further information, please contact: 
     MaxCyte Inc. 
       Doug Doerfler, Chief Executive Officer 
       Amanda Murphy, Chief Financial Officer         [phone] 
      Nominated Adviser and Joint Corporate Broker 
       Panmure Gordon 
       Emma Earl 
       Freddy Crossley 
       Corporate Broking 
       Rupert Dearden                                  [phone] 
 
       Joint Corporate Broker 
       Numis Securities Limited 
       James Black 
       Duncan Monteith                                [phone] 
      Financial PR Adviser                            [phone] 
       Consilium Strategic Communications              [e-mail] 
       Mary-Jane Elliott 
       Chris Welsh 
       Sukaina Virji 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAENEDEAEEAA

(END) Dow Jones Newswires

October 01, 2020 02:00 ET (06:00 GMT)